Page 183 - Haematologica Vol. 107 - September 2022

ARTICLE - Rituximab with LMB-chemotherapy regimen in PMLBL M.E. Dourthe et al.
immunochemotherapy for primary mediastinal B cell lymphoma
patients: a LYSA study. Blood Adv. 2021;5(19):3862-3872.
18. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-
rituximab therapy in primary mediastinal B-cell lymphoma. N
Engl J Med. 2013;368(15):1408-1416.
19. Giulino-Roth L, O’Donohue T, Chen Z, et al. Outcomes of adults
and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739-747.
20. Knörr F, Zimmermann M, Attarbaschi A, et al. Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Haematologica.
2021;106(12):3232-3235.
21. Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for high-
risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl
J Med. 2020;382(23):2207-2219.
22. Ehrhardt MJ, Chen Y, Sandlund JT, et al. Late health outcomes
after contemporary Llymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2019;37(28):2556-2570.
23. Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291-3299.
Haematologica | 107 September 2022
2182